IQVIA Holdings Inc. IQV

Zacks Investment Research 13 nov

IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research 27 oct

IQVIA Holdings reported strong Q3 2026 results with adjusted EPS of $3.34 (up 11.3% YoY) and revenues of $4.43B (up 8% YoY), both beating consensus estimates. R&D bookings jumped 15% to $3.2B with strongest clinical bookings since 2022. The company raised its 2026 revenue guidance to $17.35-$17.50B and adjusted EPS guidance to $12.90-$13.00. However, operating costs remain elevated and the stock carries a Zacks Rank #4 (Sell) rating.

Zacks Investment Research 21 oct

AxoGen is expected to report Q3 2026 earnings of $0.14 per share with 21.2% revenue growth on October 28, but carries a 0% Earnings ESP with a Zacks Rank #2, making it difficult to predict an earnings beat. Meanwhile, IQVIA is projected to post $3.24 EPS with 6.4% revenue growth, but faces a negative Earnings ESP of -0.09% combined with a Zacks Rank #4 (Sell), suggesting limited upside potential despite a history of beating estimates.

Zacks Investment Research 20 oct

IQVIA Holdings is expected to report Q3 2026 earnings on October 27, with consensus estimates of $3.24 EPS (up 8% YoY) and $4.36B in revenues (up 6.4% YoY). However, recent analyst revisions have turned slightly bearish, resulting in a negative Earnings ESP of -0.09%, making it difficult to predict an earnings beat despite the company's strong historical track record of beating estimates in the last four quarters.

Zacks Investment Research 14 oct

Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.